HC Wainwright & Co. Downgrades Acer Therapeutics to Neutral
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has downgraded Acer Therapeutics (NASDAQ:ACER) from Buy to Neutral.

September 05, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Acer Therapeutics has been downgraded from Buy to Neutral by HC Wainwright & Co.
The downgrade from Buy to Neutral by a reputable analyst firm like HC Wainwright & Co. could potentially lead to a decrease in the stock price of Acer Therapeutics in the short term as it may influence investor sentiment and decision making.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100